Abstract: A medical analysis device with cellular impedance signal processing comprises a memory (4) arranged to receive pulse data sets, each pulse data set comprising impedance value data that are associated each time with a time marker, these data together representing a curve of cellular impedance values that are measured as a cell passes through a polarised opening. This device further comprises a classifier (6) comprising a convolutional neural network receiving the pulse data sets as input and is provided with at least one convolutional layer, which convolutional layer has a depth greater than or equal to 3, and at least two fully connected layers, in addition to an output layer rendering a cell classification from which a pulse data set is derived.

Abstract: A device for medical analyses with cellular impedance signal processing comprises a memory (4) arranged to receive pulse data sets, each pulse data set comprising impedance value data that are associated each time with a time marker, these data together representing a curve of cellular impedance values that are measured as a cell passes through a polarized opening, a computer (6) arranged to process a pulse data set by determining a rotation value indicating whether the cell from which this pulse data set has been taken has undergone a rotation during its passage through the polarized opening, and a classifier (8) arranged to retrieve from the computer (6) a given pulse data set, and to use the resulting rotation value to classify the given pulse data set in a rotation pulse data set group (10) or a rotationless pulse data set group (12).

Abstract: The present findings point to mutant HSCs as the cause of BM neuroglial damage that compromises MSC survival and function, critically contributing to MPN pathogenesis. In this sense, the present invention shows that the niche damage triggered by the mutant HSC is essential for the development of a haematopoietic malignancy previously considered to be caused by the HSC alone. Targeting HSC niche-forming MSCs and their neural regulation paves the way to more efficient therapeutic strategies in MPN. For this purpose, the present invention shows that an efficient therapeutic strategy for the treatment of MPN lies on the administration of neuroprotective compounds, such as 4-methylcatechol, capable of protecting BM sympathetic nerve fibers. Additionally, another efficient therapeutic strategy is shown herein as the administration of selective ?3-adrenergic agonists such as BRL37344 or Mirabegron, since this strategy will compensate for deficient sympathetic stimulation of nestin+ MSCs.

Abstract: The present findings point to mutant HSCs as the cause of BM neuroglial damage that compromises MSC survival and function, critically contributing to MPN pathogenesis. In this sense, the present invention shows that the niche damage triggered by the mutant HSC is essential for the development of a haematopoietic malignancy previously considered to be caused by the HSC alone. Targeting HSC niche-forming MSCs and their neural regulation paves the way to more efficient therapeutic strategies in MPN. For this purpose, the present invention shows that an efficient therapeutic strategy for the treatment of MPN lies on the administration of neuroprotective compounds, such as 4-methylcatechol, capable of protecting BM sympathetic nerve fibres. Additionally, another efficient therapeutic strategy is shown herein as the administration of selective ?3-adrenergic agonists such as BRL37344 or Mirabegron, since this strategy will compensate for deficient sympathetic stimulation of nestin+ MSCs.

Abstract: The present invention relates to the use of at least one isolated multipotent stem cell for maintaining haematopoiesis in vitro, in which said multipotent stem cell is preferably a mesenchymal stem cell or, more preferably, said mesenchymal stem cell is a mesenchymal stem cell capable of expressing the nestin protein. The present invention also relates to an isolated cell population of adult nestin-positive mesenchymal cells from a mammal, including humans, to the use thereof for producing a drug for maintaining haematopoiesis in a mammal, for the prevention and/or treatment of at least one disease associated with a malfunction in maintaining haematopoiesis in a mammal, and for maintaining and expanding adult haematopoietic stem cells of said mammal, including a human. Furthermore, the present invention also relates to a method for maintaining haematopoiesis in vitro or to a method for evaluating the haematopoietic capacity of a mammal.